Literature DB >> 23689117

Clinical routine utility of basophil activation testing for diagnosis of hymenoptera-allergic patients with emphasis on individuals with negative venom-specific IgE antibodies.

Peter Korošec1, Mira Šilar, Renato Eržen, Nina Čelesnik, Nissera Bajrović, Mihaela Zidarn, Mitja Košnik.   

Abstract

BACKGROUND: Previous reports suggest the usefulness of basophil activation testing (BAT) in Hymenoptera-allergic patients with negative venom-specific IgE antibodies. We sought to evaluate the diagnostic utility of this testing in a routine clinical laboratory setting.
MATERIALS AND METHODS: Twenty-one patients with anaphylactic reactions to Hymenoptera sting (median grade III) and negative venom-specific IgE were routinely and prospectively tested with BAT.
RESULTS: We were able to diagnose 81% (17 of 21) of patients with BAT and 57% (12 of 21) with intradermal skin testing. Three wasp venom-allergic patients showed IgE positivity to rVes v 5. Four patients (19%) were negative for all tests. In the case of double-positive BAT, the culprit insect correlated with the venom that induced a significantly higher basophil response.
CONCLUSIONS: BAT allows the identification of severe Hymenoptera-allergic patients with negative specific IgE and skin tests. The routine use of this cellular test should facilitate prescription of venom immunotherapy in complex cases with inconclusive diagnostic results.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23689117     DOI: 10.1159/000348500

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  15 in total

Review 1.  Component Resolved Diagnosis in Hymenoptera Anaphylaxis.

Authors:  D Tomsitz; K Brockow
Journal:  Curr Allergy Asthma Rep       Date:  2017-06       Impact factor: 4.806

2.  [Tricky cases in in-vitro diagnostics of hymenoptera venom allergy].

Authors:  S Müller; D Rafei-Shamsabadi; T Jakob
Journal:  Hautarzt       Date:  2014-09       Impact factor: 0.751

Review 3.  Venom immunotherapy: an updated review.

Authors:  Darío Antolín-Amérigo; Carmen Moreno Aguilar; Arantza Vega; Melchor Alvarez-Mon
Journal:  Curr Allergy Asthma Rep       Date:  2014-07       Impact factor: 4.806

Review 4.  Immunotherapy in allergy and cellular tests: state of art.

Authors:  Salvatore Chirumbolo
Journal:  Hum Vaccin Immunother       Date:  2014-05-02       Impact factor: 3.452

Review 5.  Pros and Cons of Clinical Basophil Testing (BAT).

Authors:  Hans Jürgen Hoffmann; Edward F Knol; Martha Ferrer; Lina Mayorga; Vito Sabato; Alexandra F Santos; Bernadette Eberlein; Anna Nopp; Donald MacGlashan
Journal:  Curr Allergy Asthma Rep       Date:  2016-07       Impact factor: 4.806

Review 6.  Facing Hymenoptera Venom Allergy: From Natural to Recombinant Allergens.

Authors:  Amilcar Perez-Riverol; Débora Lais Justo-Jacomini; Ricardo de Lima Zollner; Márcia Regina Brochetto-Braga
Journal:  Toxins (Basel)       Date:  2015-07-09       Impact factor: 4.546

Review 7.  Component resolved diagnostics for hymenoptera venom allergy.

Authors:  Thilo Jakob; Ulrich Müller; Arthur Helbling; Edzard Spillner
Journal:  Curr Opin Allergy Clin Immunol       Date:  2017-10

8.  Diagnostics in Hymenoptera venom allergy: current concepts and developments with special focus on molecular allergy diagnostics.

Authors:  Thilo Jakob; David Rafei-Shamsabadi; Edzard Spillner; Sabine Müller
Journal:  Allergo J Int       Date:  2017-04-11

Review 9.  Allergen-specific immunotherapy of Hymenoptera venom allergy - also a matter of diagnosis.

Authors:  Maximilian Schiener; Anke Graessel; Markus Ollert; Carsten B Schmidt-Weber; Simon Blank
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

10.  Down-regulation of FcεRI-mediated CD63 basophil response during short-term VIT determined venom-nonspecific desensitization.

Authors:  Nina Čelesnik Smodiš; Mira Šilar; Renato Eržen; Matija Rijavec; Mitja Košnik; Peter Korošec
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.